Compare Genuine Parts Company (GPC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Illumina, Inc. — how do they compare? Genuine Parts Company trades at $127.35 (market cap $17.67B), while Illumina, Inc. trades at $275.75 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.3× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.32% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Illumina, Inc. for 83 Days on average.
| GPC | ILMN | |
|---|---|---|
Market Cap | $17.67B | $39.95B |
Volume | 1,079,458 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $293.69 |
52-Week Low | $92.47 | $91.00 |
Typical Hold Time | 75 Days | 83 Days |
Enterprise Value | $23.76B | $41.31B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $127.16, up 1.4% today, near its pivot point of $127 with technical indicators showing a bullish trend. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20. Revenue growth is steady, but net income margins have compressed significantly to 0.13% in 2025. Analysts maintain a consensus price target of $145.75, with 43% recommending Buy. Key developments include the planned spinoff of its industrial unit, Motion, scheduled for Q1 2027.
The outlook for GPC is cautiously optimistic, driven by the potential value unlock from the corporate split and its position in the resilient automotive aftermarket. However, thin profit margins and rising debt levels pose risks. The stock offers a dividend yield supported by its Dividend King status, but investors should weigh execution risks around the separation against the prospect of segment-specific reratings.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
